


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:


1. (Previously Presented) A purified compound of general formula **I**:



wherein R₁ are each independently selected from the group consisting of hydrogen, halogen, cyano, hydroxyl, nitro, azido, substituted or unsubstituted alkyl, substituted or unsubstituted alkylidene, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group and substituted or unsubstituted acyl; R₃ groups are each independently selected from the group consisting of hydrogen, halogen, cyano, hydroxyl, nitro, azido, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group and substituted or unsubstituted acyl

R₄ groups are each independently selected from NR₂, O and S; and R₂ groups are each independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkoxy and substituted or unsubstituted acyl, or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof.

2. (Original) The compound according to claim 1, having the following formula II:



wherein R₁, R₂, R₃ and R₄ are as defined in claim 1.


3. (Previously Presented) The compound according to claim 1, wherein R₁ are each independently selected from substituted or unsubstituted alkyl and substituted or unsubstituted alkylidene.

4. (Previously Presented) The compound according to claim 1, wherein R₂ are each independently selected from H and substituted or unsubstituted alkyl.

6. (Previously Presented) The compound according to claim 1, wherein R₄ are each O.

or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof.

8. (Original) The compound according to claim 7, having the following stereochemistry



9. (Original) A process for producing a compound as defined in claim 1 which comprises synthesising an oxazole/thiazole/imidazole fragment, and introducing an aminoacidic fragment.

10. (Currently Amended) A process for preparing a compound as defined in claim 4 7 which comprises (i) cultivating a substantially pure culture strain ES7-008, available under accession number CECT 3358, from the Colección Espanola de Cultivos Tipo at the University of Valencia, Spain microorganism strain of the *Thermoactinomyces* genus capable of producing it and (ii) isolating said compound from the cultured broth.

Claims 11-13 are cancelled.

14. (Previously Presented) A pharmaceutical composition comprising a compound as defined in claim 1, or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof, and a pharmaceutically acceptable diluent or carrier.

15. (Cancelled)

16. (Cancelled)

17. (Previously Presented) A method of treatment of cancer which comprises administering an effective amount of a compound as defined in claim 1, or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof.

18. (Previously Presented) The process of claim 10, wherein the cultivating is performed in an aqueous nutrient medium with assimilable carbon and nitrogen sources and salts.